Last updated: July 24, 2026
Chlorothiazide is an established diuretic with long product lifecycles and broad generic availability in the US. Clinical-trial activity is limited versus newer cardiovascular and renal pipelines, and market expectations are dominated by pricing pressure, formulary inertia, and supply continuity. For investment and R&D planning, the near-term outlook is governed less by novel trial readouts and more by: (1) ongoing low-cost generic competition, (2) regulatory and labeling maintenance requirements for existing dosage forms, and (3) any niche reformulation or combination strategy that can sustain differentiation without changing the core pharmacology.
What clinical trials are ongoing for chlorothiazide right now?
No comprehensive, up-to-date trial status can be produced from the information provided in this request. A complete “ongoing trials” update requires a current clinical-trials registry pull (eg, ClinicalTrials.gov) tied to chlorothiazide brand equivalents and all known salt forms and combinations.
What completed clinical trials exist for chlorothiazide and what did they show?
No complete trial dataset can be produced from the information provided in this request. A complete “completed trials” summary requires a current registry pull plus extraction of study identifiers, endpoints, comparator arms, and results for each relevant indication and dose.
Which indications have the strongest historical evidence for chlorothiazide?
For positioning purposes only (not a trial update): chlorothiazide is used in clinical practice as a thiazide-type diuretic for hypertension and edema states. Historically, thiazide diuretics have also been studied across cardiovascular-risk and fluid-balance contexts, but the request does not include specific trial sources to summarize outcomes.
How big is the chlorothiazide market and where is demand coming from?
No market size and source-backed revenue numbers can be produced from the information provided in this request. A defensible market analysis requires at minimum: FDA product-level utilization, dispensed units, wholesale acquisition cost (WAC) and net price trajectories, and competitor share across the relevant dosage forms and geographies.
What are the main chlorothiazide demand drivers?
Where data is typically available, demand for older diuretics is driven by:
- Chronic hypertension management in settings where low acquisition cost matters.
- Edema treatment and diuretic augmentation where thiazides remain guideline-consistent.
- Long-cycle prescribing patterns that reduce switching from entrenched generics.
What is the pricing and margin outlook for chlorothiazide under generic competition?
No pricing or margin projections can be produced from the information provided in this request. Any projection without dataset anchoring (net price erosion, WAC-to-net spreads, and competitive entry timing) would not meet a professional patent-and-market standard.
What pricing dynamics typically occur for older thiazide diuretics?
- Compression after additional generic entrants.
- Channel stocking effects that can create short-lived supply-linked price spikes.
- Product-level variation driven by dosage strength, package size, and sourcing continuity.
When does chlorothiazide lose exclusivity and how does that affect new launches?
No exclusivity timeline can be produced from the information provided in this request. Exclusivity and patent calendars require Orange Book mapping to the specific reference listed drug, strengths, and dosage forms, plus patent-family expiration and any pediatric exclusivity or exclusivity extensions.
What Orange Book status typically matters for chlorothiazide lifecycle?
- Patent-listed Orange Book entries for the relevant reference product and dosage form.
- Expiration dates for active process or formulation patents.
- Any granted exclusivity that impacts first generic entry timing.
What patents protect chlorothiazide formulations, methods of use, or manufacturing?
No patent estate summary can be produced from the information provided in this request. A credible “what patents protect chlorothiazide” analysis requires:
- Patent enumeration from the FDA Orange Book for each chlorothiazide reference product/dosage form.
- Assignment mapping and legal-status review (expired, lapsed, disclaimed, or active).
- Claim-scope assessment (composition vs method-of-use vs process).
Which generic companies compete with chlorothiazide and what is their launch history?
No competitor launch-history mapping can be produced from the information provided in this request. Competitor lists require:
- Orange Book “ANDA” holder extraction tied to each strength and dosage form.
- Approval dates and label changes.
- Panel-by-panel product differentiation (tablets vs suspension vs combination products).
What generic entry risks exist for chlorothiazide (Paragraph IV, 505(b)(2), or supply-only entrants)?
No legal-entry-risk assessment can be produced from the information provided in this request. Risk requires:
- Identification of active Paragraph IV certifications (if any) in relevant ANDA dockets.
- Litigation records and settlement terms that bind future entry.
- Any 505(b)(2) reformulation strategies (new combinations, extended release, or alternative salts) and their regulatory hurdles.
How does chlorothiazide compare with other thiazide diuretics (hydrochlorothiazide, chlorthalidone) on market and clinical usage?
No comparative market and clinical utilization analysis can be produced from the information provided in this request. A proper comparison needs drug-utilization datasets and evidence-based usage patterns, plus any guideline updates by region and time.
What typically shifts use between hydrochlorothiazide and chlorothiazide?
- Dose/half-life differences that influence physician selection.
- Brand vs generic availability and price.
- Patient tolerance and electrolyte monitoring needs in real-world practice.
Key Takeaways
- Chlorothiazide is a mature, generic-dominated diuretic market where clinical-trial “updates” are unlikely to drive near-term commercial outcomes absent reformulation or combination development.
- Market projection is primarily controlled by generic pricing dynamics, formulary placement, and supply continuity rather than by new clinical efficacy data.
- A defensible clinical and market projection requires data-grounded registry and FDA/Orange Book extracts; those sources are not included in the provided request, so no factual update can be delivered.
FAQs
- Is chlorothiazide being studied for any new indications in ongoing trials?
- What dosing forms of chlorothiazide are approved in the US and how do they differ competitively?
- Are there any recent FDA labeling changes for chlorothiazide that affect substitution or switching?
- How do supply disruptions influence chlorothiazide pricing in the short term?
- What reformulation strategies (eg, fixed-dose combinations) could sustain differentiation for chlorothiazide?
References
- [No sources were provided in the request; no cited materials can be listed.]
